E Fund Management Co. Ltd. Purchases Shares of 45,895 Celcuity, Inc. $CELC

E Fund Management Co. Ltd. purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the second quarter, Holdings Channel.com reports. The firm purchased 45,895 shares of the company’s stock, valued at approximately $4,802,000.

Several other institutional investors have also recently made changes to their positions in CELC. Creative Planning purchased a new position in Celcuity during the second quarter worth about $177,000. Rhumbline Advisers raised its holdings in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after acquiring an additional 503 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Celcuity in the 2nd quarter valued at about $169,000. Quantinno Capital Management LP boosted its position in shares of Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after acquiring an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co boosted its position in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after acquiring an additional 60,849 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on CELC. Citizens Jmp restated a “market outperform” rating and issued a $177.00 price objective on shares of Celcuity in a research report on Monday. Needham & Company LLC decreased their price target on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Wall Street Zen downgraded shares of Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Wells Fargo & Company cut their target price on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $154.55.

Celcuity Stock Up 0.4%

Shares of NASDAQ CELC opened at $93.64 on Thursday. The stock has a market capitalization of $4.58 billion, a P/E ratio of -21.78 and a beta of 0.20. Celcuity, Inc. has a one year low of $44.42 and a one year high of $151.02. The firm’s 50 day simple moving average is $94.10 and its two-hundred day simple moving average is $107.95. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, analysts expect that Celcuity, Inc. will post -4.51 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.